scholarly article | Q13442814 |
P356 | DOI | 10.1002/CPDD.430 |
P698 | PubMed publication ID | 29276940 |
P50 | author | David J. Greenblatt | Q88911712 |
P2860 | cites work | Treatment of Opioid-Use Disorders | Q26741303 |
Opioid Abuse in Chronic Pain--Misconceptions and Mitigation Strategies | Q26749305 | ||
National Institutes of Health Pathways to Prevention Workshop: the role of opioids in the treatment of chronic pain | Q34457780 | ||
CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. | Q34518212 | ||
New Data on Opioid Use and Prescribing in the United States | Q38688794 | ||
Vital Signs: Changes in Opioid Prescribing in the United States, 2006-2015. | Q38690977 | ||
Addressing the Fentanyl Threat to Public Health | Q40334990 | ||
Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin | Q41245913 | ||
State laws regulating prescribing of controlled substances: balancing the public health problems of chronic pain and prescription painkiller abuse and overdose | Q42266030 | ||
A Proactive Response to Prescription Opioid Abuse | Q44335156 | ||
Improving Outcomes for Persons With Opioid Use Disorders: Buprenorphine Implants to Improve Adherence and Access to Care | Q44338786 | ||
The Role of Science in Addressing the Opioid Crisis | Q44346078 | ||
Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety | Q88932849 | ||
P433 | issue | 1 | |
P304 | page(s) | 6-8 | |
P577 | publication date | 2018-01-01 | |
P1433 | published in | Clinical pharmacology in drug development | Q27726600 |
P1476 | title | Opioid Prescribing: What Are the Numbers? | |
P478 | volume | 7 |
Q90040560 | Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials | cites work | P2860 |
Search more.